Ingevity (NYSE:NGVT – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 5.000-5.450 for the period, compared to the consensus EPS estimate of 4.950. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion.
Analysts Set New Price Targets
NGVT has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Ingevity in a research report on Friday, July 17th. Wall Street Zen raised shares of Ingevity from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Ingevity has a consensus rating of “Hold” and a consensus target price of $80.00.
Read Our Latest Stock Analysis on NGVT
Ingevity Stock Performance
Ingevity (NYSE:NGVT – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.41. The business had revenue of $314.10 million for the quarter, compared to analysts’ expectations of $312.20 million. Ingevity had a return on equity of 261.97% and a net margin of 4.65%.Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, equities research analysts expect that Ingevity will post 5.05 EPS for the current year.
Insider Buying and Selling
In related news, SVP Terrance M. Dyer sold 496 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $68.49, for a total value of $33,971.04. Following the completion of the transaction, the senior vice president directly owned 7,202 shares of the company’s stock, valued at approximately $493,264.98. This trade represents a 6.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.88% of the company’s stock.
Institutional Investors Weigh In On Ingevity
Several institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC bought a new stake in shares of Ingevity during the 4th quarter valued at $27,000. Meeder Asset Management Inc. bought a new position in Ingevity in the 4th quarter worth about $33,000. Geneos Wealth Management Inc. boosted its stake in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after purchasing an additional 387 shares during the period. Headlands Technologies LLC purchased a new position in Ingevity during the 2nd quarter valued at about $46,000. Finally, Kestra Advisory Services LLC purchased a new position in Ingevity during the 4th quarter valued at about $47,000. Hedge funds and other institutional investors own 91.59% of the company’s stock.
Ingevity Company Profile
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Read More
- Five stocks we like better than Ingevity
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
- Peeling Out or Breaking Down? Ford’s High-Stakes Turnaround
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
